Skip to main content

Table 2 Antiviral medications approved and recommended for treatment and chemoprophylaxis of influenza

From: Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges

Antiviral agent (trade name) Activity against virus Use Safety and efficacy References
Oseltamivir (Tamiflu®) Influenza A and B Treatment Accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital [139], [140], [141], [142]
Chemoprophylaxis Modest evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations [141], [142]
Zanamivir (Relenza®) Influenza A and B Treatment Decreases the risk of becoming symptomatic [141], [143], [144], [145]
Peramivir (Rapivab®) Influenza A and B Treatment Reduces the time to alleviation of influenza symptoms [146], [147]
Baloxavir (Xofluza®) Influenza A and B Treatment Effective in alleviating influenza symptoms and reducing the viral load 1 day after initiation [148], [149], [150], [151], [57], [152]
Laninamivir (Inavir®) Influenza A and B Treatment Inhibited the NA activities, reduces duration of symptoms [153], [154], [155], [56], [156], [55]